Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 3

3(42.9%)

Phase 1

1(14.3%)

7Total

Phase 2(3)

Phase 3(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06403267Phase 2Recruiting

NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy

Role: lead

NCT04462536Phase 3Completed

Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Role: lead

NCT05636306Phase 1Completed

A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults

Role: lead

NCT02315443Phase 3Completed

Field Randomization of Nerinetide (NA-1) Therapy in Early Responders

Role: lead

NCT02930018Phase 3Completed

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke

Role: lead

NCT02056574Phase 2Withdrawn

Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured Aneurysms

Role: lead

NCT00728182Phase 2Completed

Evaluating Neuroprotection in Aneurysm Coiling Therapy

Role: lead

All 7 trials loaded